Efficacy and safety of albumin bound paclitaxel in patients with advanced cervical cancer
10.3969/j.issn.1005-1678.2017.09.013
- VernacularTitle:白蛋白结合型紫杉醇治疗晚期宫颈癌的疗效与安全性探讨
- Author:
Qiuhong QU
;
Libei WEI
;
Ling YIN
- Keywords:
albumin bound;
paclitaxel;
advanced;
cervical cancer;
efficacy;
safety
- From:
Chinese Journal of Biochemical Pharmaceutics
2017;37(9):40-41,43
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical efficacy and safety of albumin bound paclitaxel in patients with advanced cervical cancer, and to provide reference for clinical practice. Methods The hospital treated 47 cases of advanced cervical cancer patients as the observation object, from May 2015 to January 2017, the computer randomly divided into the control group and the experimental group by computer, the control group of 23 cases of advanced cervical cancer patients from time with paclitaxel chemotherapy, 24 cases of advanced cervical cancer patients were treated with albumin bound paclitaxel chemotherapy, observed patients with advanced cervical cancer after treatment of the two groups the maximum diameter of the tumor, relieve symptoms, efficacy, quality of life score, the incidence of adverse reactions were compared. Results The two groups of patients with advanced cervical cancer after treatment, there are significant differences in the observation index, statistical significance (P<0.05), in which the short-term efficacy of the experimental group is higher than the short-term efficacy of the control group by 31.52％. Conclusion For patients with advanced cervical cancer, the implementation of albumin binding paclitaxel chemotherapy can effectively improve the efficacy of the treatment of patients, high safety, worthy of clinical treatment.
